PDCD1 and neoplasm: In addition, anti-tumor γβ T cells playing a role in NSCLC are targets for both VA extracts and PD-1/PD-L1 inhibitors resulting in a further explanation for synergistic effects of ICB and add-on VA therapy [44,45,46,47].